Clinical trial
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
NCT06580002
Study timeline
Study start (actual)2024-12-02Date precision: day
Registry last updated2026-07-14
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Breast Cancerunresolved
Sarcomaunresolved
Gastric Cancerunresolved
Lung Cancerunresolved
Head and Neck Cancerunresolved
Colorectal Cancerunresolved
Ovarian Cancerunresolved
Liver Cancerunresolved
Genitourinary Cancerunresolved
Gynecologic Cancerunresolved
Urinary Bladder Cancerunresolved
Leukemiaunresolved
Lymphoid Leukemiaunresolved
Myeloma Multipleunresolved
Prostate Cancerunresolved
Pancreas Cancerunresolved
Non-hodgkin Lymphomaunresolved
Hodgkin Lymphomaunresolved
Brain Cancerunresolved
Melanomaunresolved
Mycosis Fungoidesunresolved
Kidney Cancerunresolved
Interventions
RiluzoleDRUG · verified · RxNorm: riluzole
PlaceboDRUG
Sponsors & collaborators
University of California, Irvinelead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT06580002 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.